Biologics Kill Biosimilars? Limited Originator Uptake Perplexes China Biogenerics Market
Executive Summary
Although hope is high for the first follow-on biologic to take off in the world's second-largest pharma market, China's biosimilar developers see choppy waters ahead. Biosimilars are not only limited by uncertain pricing and murky interchangeability rules, but also by extremely low biologic penetration and developers rushing to develop I/O and cell therapies.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.